PharmaTelevision - Ian Nicholson of Chroma Therapeutics discusses their recent deal with CTI

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Ian Nicholson of Chroma Therapeutics discusses their recent deal with CTI

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Ian Nicholson, CEO at Chroma Therapeutics

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Chroma Therapeutics:Products and Technology Platform

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at the Oxford Studios of PharmaTelevision. On this show I have Ian Nicholson, who is CEO of Chroma Therapeutics based here in Oxfordshire, welcome to the show.

Ian Nicholson:

Thank you Fintan Walton and good morning to you.

Fintan Walton:

Good morning to you. Ian, Chroma Therapeutics is a British biotechnology company as I said based here in Oxfordshire, tell us just little bit about the history of Chroma Therapeutics and then could you tell me little bit about your products?

Ian Nicholson:

Yes, of course Fintan. So Chroma is a private biotech company probably one of the better known in the UK now, The company started off as really one of the first epigenetic companies to be founded anywhere in the world actually in 2001, since 2004 when the company was properly financed we've developed really a set of clinical assets focused in niche areas of unmet clinical need in blood bone cancers, leukemia's, lymphoma's, myeloma but we've also developed a very novel chemistry platform which we've exploited now to the point at which we've signed a significant partnership with GSK around that platform.

Fintan Walton:

Okay, well the important thing is the platform of course you've also got a product which will come on to which is moving Phase II to Phase III, but tell us about the platform because it's quite a unique technology which is not just applicable to one particular type of drug but to the whole platform of potential drugs?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Ian Nicholson

Chief Executive Officer

Dr. Ian Nicholson , joined Chroma in September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech, responsible for all global licensing activities, and additionally held the position of Acting CEO, Oxford GlycoSciences following its acquisition by Celltech. Prior to this he was Commercial Director at Oxford Asymmetry and has held a variety of senior commercial positions with Lonza and Amersham. He holds a BSc (Hons) degree from University College, London and an MBA from Boston University.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Chroma Therapeutics

Chroma Therapeutics based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilizing its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Phase4 and The Wellcome Trust.